Hasil Pencarian - Rodolfo Perini

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Superação prospectiva (prospective overruling) como regra - (in)segurança jurídica em caso de virada jurisprudencial

    Superação prospectiva (prospective overruling) como regra - (in)segurança jurídica em caso de virada jurisprudencial oleh Rodolfo Perini Gomes

    Diterbitkan 2020-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

    Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study oleh Masatoshi Eto, Toshio Takagi, Go Kimura, Satoshi Fukasawa, Satoshi Tamada, Yuji Miura, Mototsugu Oya, Naoto Sassa, Satoshi Anai, Masahiro Nozawa, Hideki Sakai, Rodolfo Perini, Wataru Yusa, Hiroki Ikezawa, Tomoyuki Narita, Yoshihiko Tomita

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

    A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECH... oleh Primo N. Lara, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo Perini, Toni K. Choueiri, Robert J. Motzer

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

    Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms oleh Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

    Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms oleh Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: